Partnerships and collaborations

Our mission at xCures is to help patients and oncologists utilize any and all resources to fight advanced cancer. As a technology platform, we offer information and decision support directly to patients and oncologists. We also connect them with third-party resources from some of the best ‘patient first’ organizations to expand treatment options and services.

  • Aetion

    xCures has joined Aetion in the launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative.

    Visit Aetion

  • BioMed Valley Discoveries

    BioMed Valley Discoveries partnered with xCures to offer expanded access to ulixertinib, an ERK1/2 inhibitor for patients with advanced solid tumors no longer responding to standard of care. Learn More

    Visit BioMed Valley Discoveries

  • BioSpark

    BioSpark partnered with xCures to rapidly expand the scope of real-world oncology data and help patients and their physicians understand the best treatment options

    Visit BioSpark

  • Cellworks

    Cellworks partnered with xCures to advance predictive algorithms based on molecular systems biology and personalize oncology through multi-omic therapy biosimulation.

    Visit Cellworks

  • Cancer Commons

    Cancer Commons partners with xCures to provide a highly customized and personal experience for advanced cancer patients in need of treatment options.

    Visit Cancer Commons


    COLONTOWN collaborates with xCures to create a comprehensive precision medicine resource for COLONTOWN University.


  • Critical Path Institute

    The Critical Path Institute partnered with xCures to quickly abstract and structure clinical data to support drug repurposing studies in rare cancers.

    Visit Critical Path Institute

  • CureMatch

    xCures partnered with CureMatch to leverage their proprietary curated knowledge base and help match patients to the best therapy options based on the unique molecular makeup of their tumor.

    Visit CureMatch

  • CureScience

    xCures’ partnership with CureScience serves to better identify specific patients and patient populations that may benefit from a particular test or treatment.

    Visit CureScience

  • DIPG/DMG Research Funding Alliance

    DDRFA partnered with xCures to streamline DMG & DIPG research and enhance patient care by centralizing the collection and analysis of anonymized DMG patient data.

    Visit DIPG/DMG Research Funding Alliance

  • DTRA

    xCures is a founding member of a historic alliance of close to a hundred life sciences and healthcare organizations that seek to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.

    Visit DTRA

  • EHE Foundation

    The EHE Foundation partnered with xCures to set up a research registry for patients with epithelioid hemangioendothelioma (EHE)

    Visit EHE Foundation

  • Endeavor

    Endeavor partnered with xCures to help screen and enroll patients who might be eligible for their PTCH1 clinical trial

    Visit Endeavor

  • Faeth

    Faeth partnered with xCures to launch a medical food clinical trial for treatment of patients with recent pancreatic adenocarcinoma or advanced PDAC and evaluate tolerability and satisfaction with the diet

    Visit Faeth

  • Fibro Fighters

    The FibroFighters Foundation is collaborating with xCures on an Observational Research Study to advance knowledge about FLHCC across the country. FLHCC is a rare cancer primarily affecting adolescents and young adults. Enroll Here

    Visit Fibro Fighters

  • Fibrolamellar Cancer Foundation

    The Fibrolamellar Cancer Foundation has partnered with xCures to drive fibrolamellar carcinoma (FLC) research and find treatment options for patients with FLC, a rare and often-fatal disease.

    Visit Fibrolamellar Cancer Foundation

  • Genome Medical

    Genome Medical and xCures have joined forces to provide genetic counselors access to xCures’ care summaries for patients based on electronic medical records from across the healthcare ecosystem.

    Visit Genome Medical

  • Institute of Systems Biology

    The Institute of Systems Biology has partnered with xCures to develop innovative clinical trials to advance systems biology algorithms in glioblastoma and multiple myeloma.

    Visit Institute of Systems Biology

  • mProbe

    mProbe partnered with xCures to leverage their targeted proteomics platform for profiling individual patients’ cancer tissues for actionable drug targets.

    Visit mProbe

  • Musella Foundation

    The Musella Foundation partnered with xCures and Cancer Commons to ensure that brain cancer patients get fast access to promising treatment options

    Visit Musella Foundation

  • Novocure

    Novocure has partnered with xCures to better understand the links between quality of life and treatment decisions, disease characteristics, and other factors for patients diagnosed with glioblastoma.

    Visit Novocure

  • Oblato

    Oblato partnered with xCures to offer OKN-007 through an expanded access program for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG)

    Visit Oblato

  • Oncoceutics

    Oncoceutics collaborated with xCures and Cancer Commons to implement an Expanded Access program for ONC201

    Visit Oncoceutics

  • PanCAN

    PanCAN partnered with xCures to give their researchers and grantees access to xCures’ de-identified data to improve research, and help their patients find the right treatments.

    Visit PanCAN

  • Patient Record Scorecard

    xCures is a supporter of the Ciitizen Patient Record Scorecard that shows how medical record providers comply with the HIPAA Right of Access based on patient requests.

    Visit Patient Record Scorecard


    xCures collaborates with POETIC, a non-profit organization that manages pediatric oncology early phase trials, to get children, adolescents, and young adults with cancer enrolled in expanded access programs of promising therapies. Learn More

    Visit POETIC

  • Prognos Health

    Prognos Health and xCures partnered to enable access to real-world oncology datasets and use continuous learning from every patient’s journey to drive insights and improve outcomes

    Visit Prognos Health

  • RenovoRx

    RenovoRx partnered with xCures to help eligible patients with locally advanced pancreatic cancer get access to the TIGeR-PaC Phase III clinical study.

    Visit RenovoRx

  • SonALAsense

    SonALAsense partnered with xCures to set up a Natural History study for DIPG and DMG, accelerating DIGP/DMG research, and ending randomization in pediatric clinical trials.

    Visit SonALAsense

  • Tyra Biosciences

    Tyra partnered with xCures for a real-world biomarker study involving patients with FGFR-mutant bladder cancer. The study investigates tumor DNA to find treatment options if the disease worsens. Learn More

    Visit Tyra Biosciences